474 related articles for article (PubMed ID: 19764381)
1. [SBU should investigate what is an evidence-based and cost-effective use of statins].
Hjemdahl P; Allhammar A; Heaton C; Hulting J; Kahan T; Malmström R; Martinsson A; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
Lakartidningen; 2009 Aug 5-18; 106(32-33):1992-4. PubMed ID: 19764381
[No Abstract] [Full Text] [Related]
2. [How far the rates of cholesterol have to be lowered in primary prevention?].
Rodondi N
Rev Med Suisse; 2010 Mar; 6(239):483-4. PubMed ID: 20373693
[No Abstract] [Full Text] [Related]
3. [2008 National Cardiology Guidelines: Prioritization requires consideration to other factors than scientific studies alone].
Eklund K; Grip L; Israelsson B; Levin LA; Lindahl B; Wallentin L
Lakartidningen; 2008 May 7-13; 105(19):1408-9; discussion 1409. PubMed ID: 18574983
[No Abstract] [Full Text] [Related]
4. Integrating economic analysis into clinical trials.
Imai K; Zhang P
Lancet; 2005 May 21-27; 365(9473):1749-50. PubMed ID: 15910936
[No Abstract] [Full Text] [Related]
5. [Treatment with statins for the reduction of cardiovascular risk].
Chiariello M
Ital Heart J Suppl; 2001 Mar; 2(3):221-3. PubMed ID: 11307779
[No Abstract] [Full Text] [Related]
6. [Statins and costs of prevented death cases].
Robberstad T
Tidsskr Nor Laegeforen; 1997 Nov; 117(28):4131. PubMed ID: 9441454
[No Abstract] [Full Text] [Related]
7. [Pfizer: TLV decision about antilipemic agents is founded on wrong basis].
Brun J; Ohlsson-Onerud A; Sörensen N
Lakartidningen; 2009 Apr 22-28; 106(17):1193-4; discussion 1194. PubMed ID: 19530431
[No Abstract] [Full Text] [Related]
8. [What has changed in therapy of vascular patients (role of statins and beta-adrenoblockers)].
Pokrovskiĭ AV; Goloviuk AL
Angiol Sosud Khir; 2010; 16(2):7-11. PubMed ID: 21032867
[TBL] [Abstract][Full Text] [Related]
9. [Say no to the extremes in the debate on lipid reduction].
Hjemdahl P; Allhammar A; Eklund J; Forslund T; Hulting J; Kahan T; Martinsson A; Malmström R; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
Lakartidningen; 2011 Sep 7-13; 108(36):1664-5. PubMed ID: 22032007
[No Abstract] [Full Text] [Related]
10. Heart protection study finds simvastatin reduces vascular risk in a wide range of high-risk patients.
Collins R
Am J Manag Care; 2002 Jan; Suppl():6. PubMed ID: 11833455
[No Abstract] [Full Text] [Related]
11. [When cholesterol lowering drugs should not be too expensive. Statins are especially effective in secondary prevention].
Thomas HP; Kassner U; Steinhagen-Thiessen E
MMW Fortschr Med; 2000 Jul; 142(30):33-4. PubMed ID: 10955017
[No Abstract] [Full Text] [Related]
12. Cardiovascular primary prevention: how high should we set the bar?
Prasad V; Vandross A
Arch Intern Med; 2012 Apr; 172(8):656-9; discussion 659. PubMed ID: 22529231
[TBL] [Abstract][Full Text] [Related]
13. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
MacNeil P
Can J Cardiol; 1998 Apr; 14 Suppl A():14A-16A. PubMed ID: 9594928
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin + ezetimibe: a combination with no proven advantages.
Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17460829
[No Abstract] [Full Text] [Related]
15. [Target levels for LDL cholesterol are put out of the running. Cholesterol should be lowered maximally in high cardiovascular risk].
Olsson AG
Lakartidningen; 2011 Jun 1-14; 108(22-23):1240-3. PubMed ID: 21786498
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients: why is someone still using the phase I diet for patients at risk for atherosclerosis?
Banks T
Am J Cardiol; 1999 Mar; 83(5):818. PubMed ID: 10080453
[No Abstract] [Full Text] [Related]
17. [Titles are power--the professors do not wish to discuss statins].
Ahnfeldt-Mollerup I; Heebøll-Nielsen NC
Ugeskr Laeger; 1998 Sep; 160(39):5680-2. PubMed ID: 9771073
[No Abstract] [Full Text] [Related]
18. In brief: Zetia and Vytorin: the ENHANCE study.
Med Lett Drugs Ther; 2008 Jan; 50(1278):5. PubMed ID: 18219263
[No Abstract] [Full Text] [Related]
19. Is there a problem with ezetimibe or just ENHANCEd hype?
Whayne TF
Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445
[No Abstract] [Full Text] [Related]
20. [Be careful about pseudo-information on cost-effectiveness].
Lindberg M
Lakartidningen; 1998 Jan; 95(3):144. PubMed ID: 9467283
[No Abstract] [Full Text] [Related]
[Next] [New Search]
